Simultaneously targeting tissue transglutaminase and kidney type glutaminase sensitizes cancer cells to acid toxicity and offers new opportunities for therapeutic intervention

Molecular Pharmaceutics

Volumn 12, Issue 1, 2015, Pages 46-55

  Katt, William P ^a   Antonyak, Marc A ^a   Cerione, Richard A ^a  

^a Animal Health Diagnostic Center   (United States)

Author keywords

cancer 968; glutaminase; tissue transglutaminase

Indexed keywords

ACYLTRANSFERASE INHIBITOR; AMMONIA; ESTROGEN RECEPTOR; HYDROLASE INHIBITOR; KIDNEY TYPE GLUTAMINASE INHIBITOR; PROGESTERONE RECEPTOR; RETINOIC ACID; TRANSGLUTAMINASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GLUTAMIC ACID; GLUTAMINE; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL; CANCER GROWTH; CELL DEATH; CELL GROWTH; CELL PH; CELL PROLIFERATION; DRUG POTENCY; DRUG TARGETING; GLIOBLASTOMA CELL LINE; GLIOMA CELL; HUMAN; HUMAN CELL; IC50; METASTASIS; PROTEIN EXPRESSION; UPREGULATION; BINDING SITE; CATALYSIS; CHEMISTRY; DRUG DESIGN; DRUG SCREENING; ENZYME ACTIVE SITE; ENZYMOLOGY; KIDNEY; NEOPLASMS; PH; TUMOR CELL LINE;

ALLOSTERIC SITE; AMMONIA; ANTINEOPLASTIC AGENTS; CATALYSIS; CATALYTIC DOMAIN; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; GLUTAMIC ACID; GLUTAMINE; GTP-BINDING PROTEINS; HUMANS; HYDROGEN-ION CONCENTRATION; INHIBITORY CONCENTRATION 50; KIDNEY; NEOPLASM METASTASIS; NEOPLASMS; TRANSGLUTAMINASES;

EID: 84920268339     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500405h     Document Type: Article

References (56)

1. Knight, Z. A.; Lin, H.; Shokat, K. M. Targeting the cancer kinome through polypharmacology Nat. Rev. Cancer 2010, 10 (2) 130-137
2. Gottesman, M. M. Mechanisms of cancer drug resistance Annu. Rev. Med. 2002, 53, 615-627
3. Harasym, T. O.; Tardi, P. G.; Harasym, N. L.; Harvie, P.; Johnstone, S. A.; Mayer, L. D. Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios Oncol. Res. 2007, 16 (8) 361-374
4. Zwick, M. B.; Wang, M.; Poignard, P.; Stiegler, G.; Katinger, H.; Burton, D. R.; Parren, P. W. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies J. Virol. 2001, 75 (24) 12198-12208
5. Greco, W. R.; Bravo, G.; Parsons, J. C. The search for synergy: a critical review from a response surface perspective Pharmacol. Rev. 1995, 47 (2) 331-385
6. Furney, S. J.; Gundem, G.; Lopez-Bigas, N. Oncogenomics methods and resources Cold Spring Harbor Protoc. 2012, 5, 546-564
7. Wang, J. B.; Erickson, J. W.; Fuji, R.; Ramachandran, S.; Gao, P.; Dinavahi, R.; Wilson, K. F.; Ambrosio, A. L.; Dias, S. M.; Dang, C. V.; Cerione, R. A. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation Cancer Cell 2010, 18 (3) 207-219
8. Katt, W. P.; Ramachandran, S.; Erickson, J. W.; Cerione, R. A. Dibenzophenanthridines as inhibitors of glutaminase C and cancer cell proliferation Mol. Cancer Ther. 2012, 11 (7) 1269-1278
9. Katt, W. P.; Cerione, R. A. Glutaminase regulation in cancer cells: a druggable chain of events Drug Discovery Today 2013, 19 (4) 450-457
10. Simpson, N. E.; Tryndyak, V. P.; Pogribna, M.; Beland, F. A.; Pogribny, I. P. Modifying metabolically sensitive histone marks by inhibiting glutamine metabolism affects gene expression and alters cancer cell phenotype Epigenetics 2012, 7 (12) 1413-1420
11. Simpson, N. E.; Tryndyak, V. P.; Beland, F. A.; Pogribny, I. P. An in vitro investigation of metabolically sensitive biomarkers in breast cancer progression Breast Cancer Res. Treat. 2012, 133 (3) 959-968
12. Warburg, O. On the origin of cancer cells Science 1956, 123 (3191) 309-314
13. Huang, W.; Choi, W.; Chen, Y.; Zhang, Q.; Deng, H.; He, W.; Shi, Y. A proposed role for glutamine in cancer cell growth through acid resistance Cell Res. 2013, 23 (5) 724-727
14. Nowik, M.; Lecca, M. R.; Velic, A.; Rehrauer, H.; Brandli, A. W.; Wagner, C. A. Genome-wide gene expression profiling reveals renal genes regulated during metabolic acidosis Physiol. Genomics 2008, 32 (3) 322-334
15. Freund, D. M.; Prenni, J. E.; Curthoys, N. P. Response of the mitochondrial proteome of rat renal proximal convoluted tubules to chronic metabolic acidosis Am. J. Physiol., Renal Physiol. 2013, 304 (2) F145-F155
16. Laterza, O. F.; Curthoys, N. P. Effect of acidosis on the properties of the glutaminase mRNA pH-response element binding protein J. Am. Soc. Nephrol. 2000, 11 (9) 1583-1588
17. Kraus, M.; Wolf, B. Implications of acidic tumor microenvironment for neoplastic growth and cancer treatment: A computer analysis Tumor Biol. 1996, 17 (3) 133-154
18. Estrella, V.; Chen, T. A.; Lloyd, M.; Wojtkowiak, J.; Cornnell, H. H.; Ibrahim-Hashim, A.; Bailey, K.; Balagurunathan, Y.; Rothberg, J. M.; Sloane, B. F.; Johnson, J.; Gatenby, R. A.; Gillies, R. J. Acidity generated by the tumor microenvironment drives local invasion Cancer Res. 2013, 73 (5) 1524-1535
19. Zhang, J.; Antonyak, M. A.; Singh, G.; Cerione, R. A. A mechanism for the upregulation of EGF receptor levels in glioblastomas Cell Rep. 2013, 3 (6) 2008-2020
20. Lorand, L.; Graham, R. M. Transglutaminases: crosslinking enzymes with pleiotropic functions Nat. Rev. Mol. Cell Biol. 2003, 4 (2) 140-156
21. Iwai, K.; Shibukawa, Y.; Yamazaki, N.; Wada, Y. Transglutaminase 2-dependent deamidation of glyceraldehyde-3-phosphate dehydrogenase promotes trophoblastic cell fusion J. Biol. Chem. 2013, 289 (8) 4989-4999
22. Badarau, E.; Collighan, R. J.; Griffin, M. Recent advances in the development of tissue transglutaminase (TG2) inhibitors Amino Acids 2013, 44 (1) 119-127
23. Caron, N. S.; Munsie, L. N.; Keillor, J. W.; Truant, R. Using FLIM-FRET to measure conformational changes of transglutaminase type 2 in live cells PLoS One 2012, 7 (8) e44159
24. Yuan, L.; Choi, K.; Khosla, C.; Zheng, X.; Higashikubo, R.; Chicoine, M. R.; Rich, K. M. Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas Mol. Cancer Ther. 2005, 4 (9) 1293-1302
25. Selkoe, D. J.; Abraham, C.; Ihara, Y. Brain transglutaminase: in vitro crosslinking of human neurofilament proteins into insoluble polymers Proc. Natl. Acad. Sci. U.S.A. 1982, 79 (19) 6070-6074
26. Siegel, M.; Khosla, C. Transglutaminase 2 inhibitors and their therapeutic role in disease states Pharmacol. Ther. 2007, 115 (2) 232-245
27. Yakubov, B.; Chen, L.; Belkin, A. M.; Zhang, S.; Chelladurai, B.; Zhang, Z. Y.; Matei, D. Small molecule inhibitors target the tissue transglutaminase and fibronectin interaction PLoS One 2014, 9 (2) e89285
28. Pietsch, M.; Wodtke, R.; Pietzsch, J.; Loser, R. Tissue transglutaminase: an emerging target for therapy and imaging Bioorg. Med. Chem. Lett. 2013, 23 (24) 6528-6543
29. Gundemir, S.; Colak, G.; Tucholski, J.; Johnson, G. V. Transglutaminase 2: a molecular Swiss army knife Biochim. Biophys. Acta 2011, 1823 (2) 406-419
30. Li, B.; Cerione, R. A.; Antonyak, M. Tissue transglutaminase and its role in human cancer progression Adv. Enzymol. Relat. Areas Mol. Biol. 2011, 78, 247-293
31. Antonyak, M. A.; McNeill, C. J.; Wakshlag, J. J.; Boehm, J. E.; Cerione, R. A. Activation of the Ras-ERK pathway inhibits retinoic acid-induced stimulation of tissue transglutaminase expression in NIH3T3 cells J. Biol. Chem. 2003, 278 (18) 15859-15866
32. Hettasch, J. M.; Bandarenko, N.; Burchette, J. L.; Lai, T. S.; Marks, J. R.; Haroon, Z. A.; Peters, K.; Dewhirst, M. W.; Iglehart, J. D.; Greenberg, C. S. Tissue transglutaminase expression in human breast cancer Lab. Invest. 1996, 75 (5) 637-645
33. Boroughs, L. K.; Antonyak, M. A.; Johnson, J. L.; Cerione, R. A. A unique role for heat shock protein 70 and its binding partner tissue transglutaminase in cancer cell migration J. Biol. Chem. 2011, 286 (43) 37094-37107
34. Antonyak, M. A.; Wilson, K. F.; Cerione, R. A. R(h)oads to microvesicles Small GTPases 2013, 3 (4) 219-224
35. Wilson, K. F.; Erickson, J. W.; Antonyak, M. A.; Cerione, R. A. Rho GTPases and their roles in cancer metabolism Trends Mol. Med. 2013, 19 (2) 74-82
36. Antonyak, M. A.; Li, B.; Boroughs, L. K.; Johnson, J. L.; Druso, J. E.; Bryant, K. L.; Holowka, D. A.; Cerione, R. A. Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells Proc. Natl. Acad. Sci. U.S.A. 2011, 108 (12) 4852-4857
37. Kim, D. S.; Park, S. S.; Nam, B. H.; Kim, I. H.; Kim, S. Y. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappa B inactivation Cancer Res. 2006, 66 (22) 10936-10943
38. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 1984, 22, 27-55
39. 2+ signals Curr. Biol. 2008, 18 (10) 781-785
40. Robinson, M. M.; McBryant, S. J.; Tsukamoto, T.; Rojas, C.; Ferraris, D. V.; Hamilton, S. K.; Hansen, J. C.; Curthoys, N. P. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) Biochem. J. 2007, 406 (3) 407-414
41. DeLaBarre, B.; Gross, S.; Fang, C.; Gao, Y.; Jha, A.; Jiang, F.; Song, J. J.; Wei, W. T.; Hurov, J. B. Full-length human glutaminase in complex with an allosteric inhibitor Biochemistry 2011, 50 (50) 10764-10770
42. Shukla, K.; Ferraris, D. V.; Thomas, A. G.; Stathis, M.; Duvall, B.; Delahanty, G.; Alt, J.; Rais, R.; Rojas, C.; Gao, P.; Xiang, Y.; Dang, C. V.; Slusher, B. S.; Tsukamoto, T. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors J. Med. Chem. 2012, 55 (23) 10551-10563
43. McConoughey, S. J.; Basso, M.; Niatsetskaya, Z. V.; Sleiman, S. F.; Smimova, N. A.; Langley, B. C.; Mahishi, L.; Cooper, A. J. L.; Antonyak, M. A.; Cerione, R. A.; Li, B.; Starkov, A.; Chaturvedi, R. K.; Beal, M. F.; Coppola, G.; Geschwind, D. H.; Ryu, H.; Xia, L.; Iisma, S. E.; Pallos, J.; Pasternack, R.; Hils, M.; Fan, J.; Raymond, L. A.; Marsh, J. L.; Thompson, L. M.; Ratan, R. R. Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease EMBO Mol. Med. 2010, 2 (9) 349-370
44. Boroughs, L. K.; Antonyak, M. A.; Cerione, R. A. A novel mechanism by which tissue transglutaminase activates signaling events that promote cell survival J. Biol. Chem. 2014, 289 (14) 10115-10125
45. Fésüs, L.; Szondy, Z. Transglutaminase 2 in the balance of cell death and survival FEBS Lett. 2005, 579 (15) 3297-3302
46. Verderio, E. A.; Johnson, T.; Griffin, M. Tissue transglutaminase in normal and abnormal wound healing: review article Amino Acids 2004, 26 (4) 387-404
47. Biederbick, A.; Kern, H. F.; Elsasser, H. P. Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vacuoles Eur. J. Cell Biol. 1995, 66 (1) 3-14
48. Maiuri, L.; Luciani, A.; Giardino, I.; Raia, V.; Villella, V. R.; D'Apolito, M.; Pettoello-Mantovani, M.; Guido, S.; Ciacci, C.; Cimminoo, M.; Cexus, O. N.; Londei, M.; Quaratino, S. Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPAR gamma down-regulation J. Immunol. 2008, 180 (11) 7697-7705
49. Zhu, J. H.; Horbinski, C.; Guo, F. L.; Watkins, S.; Uchiyama, Y.; Chu, C. T. Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death Am. J. Pathol. 2007, 170 (1) 75-86
50. Zhang, J. W.; Lesort, M.; Guttmann, R. P.; Johnson, G. V. W. Modulation of the in situ activity of tissue transglutaminase by calcium and GTP J. Biol. Chem. 1998, 273 (4) 2288-2295
51. Tovar-Vidales, T.; Roque, R.; Clark, A. F.; Wordinger, R. J. Tissue transglutaminase expression and activity in normal and glaucomatous human trabecular meshwork cells and tissues Invest. Ophthalmol. Vis. Sci. 2008, 49 (2) 622-628
52. Mattson, M. P.; Chan, S. L. Calcium orchestrates apoptosis Nat. Cell Biol. 2003, 5 (12) 1041-1043
53. Orrenius, S.; Zhivotovsky, B.; Nicotera, P. Regulation of cell death: the calcium-apoptosis link Nat. Rev. Mol. Cell Biol. 2003, 4 (7) 552-565
54. Keillor, J. W.; Chica, R. A.; Chabot, N.; Vinci, V.; Pardin, C.; Fortin, E.; Gillet, S. M. F. G.; Nakano, Y.; Kaartinen, M. T.; Pelletier, J. N.; Lubell, W. D. The bioorganic chemistry of transglutaminase: from mechanism to inhibition and engineering Can. J. Chem. 2008, 86 (4) 271-276
55. Stenberg, P.; Curtis, C. G.; Wing, D.; Tong, Y. S.; Credo, R. B.; Gray, A.; Lorand, L. Transamidase kinetics. Amide formation in the enzymic reactions of thiol esters with amines Biochem. J. 1975, 147 (1) 155-163
56. Lee, K. N.; Fesus, L.; Yancey, S. T.; Girard, J. E.; Chung, S. I. Development of selective inhibitors of transglutaminase. Phenylthiourea derivatives J. Biol. Chem. 1985, 260 (27) 14689-14694